Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Puma Biotechnology Inc’s stock clocked out at $3.58, up 0.56% from its previous closing price of $3.56. In other words, the price has increased by $0.56 from its previous closing price. On the day, 0.13 million shares were traded. PBYI stock price reached its highest trading level at $3.61 during the session, while it also had its lowest trading level at $3.53.
Ratios:
To gain a deeper understanding of PBYI’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.70. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.53. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.11.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when WILSON TROY EDWARD sold 10,800 shares for $3.40 per share. The transaction valued at 36,720 led to the insider holds 43,550 shares of the business.
Stuglik Brian M sold 8,100 shares of PBYI for $27,459 on Jun 13 ’25. The Director now owns 94,958 shares after completing the transaction at $3.39 per share. On Jun 13 ’25, another insider, Senderowicz Adrian, who serves as the Director of the company, sold 27,000 shares for $3.40 each. As a result, the insider received 91,800 and left with 27,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 177704400 and an Enterprise Value of 138805664. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.65, and their Forward P/E ratio for the next fiscal year is 15.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76 while its Price-to-Book (P/B) ratio in mrq is 1.83. Its current Enterprise Value per Revenue stands at 0.596 whereas that against EBITDA is 2.852.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.30, which has changed by 0.21355927 over the last 52 weeks, in comparison to a change of 0.12792087 over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $4.13, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is 8.38%, while the 200-Day Moving Average is calculated to be 17.24%.
Shares Statistics:
It appears that PBYI traded 355.76K shares on average per day over the past three months and 332970 shares per day over the past ten days. A total of 49.62M shares are outstanding, with a floating share count of 37.28M. Insiders hold about 24.89% of the company’s shares, while institutions hold 53.40% stake in the company. Shares short for PBYI as of 1749772800 were 2676107 with a Short Ratio of 7.52, compared to 1747267200 on 2867287. Therefore, it implies a Short% of Shares Outstanding of 2676107 and a Short% of Float of 6.3200004000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Puma Biotechnology Inc (PBYI) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.19, with high estimates of $0.19 and low estimates of $0.19.
Analysts are recommending an EPS of between $0.69 and $0.69 for the fiscal current year, implying an average EPS of $0.69. EPS for the following year is $0.5, with 1.0 analysts recommending between $0.5 and $0.5.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $52M. It ranges from a high estimate of $52M to a low estimate of $52M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $47.1MFor the next quarter, 1 analysts are estimating revenue of $57.5M. There is a high estimate of $57.5M for the next quarter, whereas the lowest estimate is $57.5M.
A total of 1 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $220M, while the lowest revenue estimate was $220M, resulting in an average revenue estimate of $220M. In the same quarter a year ago, actual revenue was $230.5MBased on 1 analysts’ estimates, the company’s revenue will be $218M in the next fiscal year. The high estimate is $218M and the low estimate is $218M.
